このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Glenmark Pharmaceuticals マネジメント
マネジメント 基準チェック /14
Glenmark Pharmaceuticals'の CEO はGlenn Saldanhaで、 Jan2001年に任命され、 の在任期間は 23.42年です。 の年間総報酬は₹ 161.85Mで、 80.2%給与と19.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.35%を直接所有しており、その価値は₹ 1.18B 。経営陣と取締役会の平均在任期間はそれぞれ1.6年と12.5年です。
主要情報
Glenn Saldanha
最高経営責任者
₹161.9m
報酬総額
| CEO給与比率 | 80.2% |
| CEO在任期間 | 23.5yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 1.7yrs |
| 取締役会の平均在任期間 | 12.5yrs |
経営陣の近況
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Recent updates
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
報酬と市場: Glennの 総報酬 ($USD 1.94M ) は、 Indian市場 ($USD 519.16K ) の同規模の企業の平均を上回っています。
報酬と収益: Glennの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Glenn Saldanha (54 yo)
23.5yrs
在職期間
₹161,850,000
報酬
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 23.5yrs | ₹161.85m | 0.35% ₹ 1.3b | |
| Global CFO & Executive Director | 6.7yrs | ₹102.47m | データなし | |
| Executive Director of Corporate Services & Executive Director | no data | ₹45.86m | 0.27% ₹ 982.6m | |
| Company Secretary & Compliance Officer | 7.4yrs | ₹5.71m | データなし | |
| President and Chief Human Resources Officer | 2.5yrs | データなし | データなし | |
| President & Head of Global Pharmaceutical Development | 1.8yrs | データなし | データなし | |
| President & Chief Quality Officer | less than a year | データなし | データなし | |
| President & Global Head of Formulation Operations | less than a year | データなし | データなし | |
| President & Business Head of India Formulations | less than a year | データなし | データなし | |
| President and Business Head of Europe & Emerging Markets | 1.5yrs | データなし | データなし | |
| President & Business Head of North America | less than a year | データなし | データなし | |
| Investor Relations Officer | no data | データなし | データなし |
1.7yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: GLENMARKの経営陣は 経験豊富 とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 25.8yrs | ₹161.85m | 0.35% ₹ 1.3b | |
| Global CFO & Executive Director | 6.2yrs | ₹102.47m | データなし | |
| Executive Director of Corporate Services & Executive Director | 24.8yrs | ₹45.86m | 0.27% ₹ 982.6m | |
| Non Executive Director | 18.9yrs | ₹400.00k | 0.39% ₹ 1.4b | |
| Non-Executive Independent Director | 22.2yrs | ₹1.70m | 0.039% ₹ 141.4m | |
| Independent Non-Executive Director | 1.4yrs | ₹100.00k | データなし | |
| Independent Non-Executive Director | 3.9yrs | ₹900.00k | データなし | |
| Independent Non-Executive Director | 5.3yrs | ₹1.30m | データなし |
12.5yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: GLENMARKの 取締役会 は経験豊富で 経験豊富 です ( 12.5年の平均在任期間)。